Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFRY ALAN JACQMEIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1588624761
CMS profile
117341
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$193.80

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $193.80 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $126.08 1
AstraZeneca Pharmaceuticals LP $67.72 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFRY ALAN JACQMEIN

NPI 1588624761 · CMS profile ID 117341

Allopathic & Osteopathic Physicians / Family Medicine

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $193.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $126.0811/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141579567 CMS
AstraZeneca Pharmaceuticals LP $67.7205/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105715512 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2024 $193.80 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,267,086.60 104
PY2024 Recipient $1,250.00 1
PY2024 Principal investigator $2,152,633.93 77
PY2023 Recipient $1,250.00 1
PY2023 Principal investigator $2,337,900.80 1,040
PY2022 Principal investigator $878,603.36 715
PY2021 Principal investigator $421,556.50 35
PY2020 Principal investigator $639,049.71 93
PY2019 Principal investigator $963,118.36 129

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

104 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $500.00 12/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006461
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 12/18/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220999233
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 12/17/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789056
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 12/09/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220818656
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789048
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,797.00 12/01/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220818654
Principal investigator 1 ModernaTX, Inc. $13,791.72 11/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974253
Principal investigator 1 ModernaTX, Inc. $63,120.75 11/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974271
Principal investigator 1 ModernaTX, Inc. $5,430.96 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998685
Principal investigator 1 ModernaTX, Inc. $418.14 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998687
Principal investigator 1 ModernaTX, Inc. $2,325.51 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998689
Principal investigator 1 ModernaTX, Inc. $5,763.57 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998693
Principal investigator 1 ModernaTX, Inc. $2,915.48 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998695
Principal investigator 1 ModernaTX, Inc. $5,819.76 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998699
Principal investigator 1 ModernaTX, Inc. $2,630.70 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998701
Principal investigator 1 ModernaTX, Inc. $2,473.24 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998705
Principal investigator 1 ModernaTX, Inc. $5,352.45 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998707
Principal investigator 1 ModernaTX, Inc. $2,171.86 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998711
Principal investigator 1 ModernaTX, Inc. $2,743.38 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998713
Principal investigator 1 ModernaTX, Inc. $5,134.00 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998717
Principal investigator 1 ModernaTX, Inc. $5,122.44 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998719
Principal investigator 1 ModernaTX, Inc. $3,796.72 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998721
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 11/19/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789054
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/11/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220999231
Principal investigator 1 ModernaTX, Inc. $338.00 11/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974239
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789046
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 10/28/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220999229
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789050
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789052
Principal investigator 1 ModernaTX, Inc. $300.00 10/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998691
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998703
Principal investigator 1 ModernaTX, Inc. $4,000.00 10/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998715
Principal investigator 1 ModernaTX, Inc. $750.00 10/15/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998725
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789044
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,500.00 09/23/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220818652
Principal investigator 1 ModernaTX, Inc. $2,142.00 09/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974257
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 09/10/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220999227
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789042
Principal investigator 1 ModernaTX, Inc. $197.60 08/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006453
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998727
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789034
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789036
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789038
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220789040
Principal investigator 1 ModernaTX, Inc. $930.00 07/30/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974245
Principal investigator 1 ModernaTX, Inc. $837.32 06/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006425
Principal investigator 1 ModernaTX, Inc. $72,846.84 06/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006451
Principal investigator 1 ModernaTX, Inc. $38,935.38 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006431
Principal investigator 1 ModernaTX, Inc. $29,402.88 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006447
Principal investigator 1 ModernaTX, Inc. $18,455.19 05/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006457
Principal investigator 1 ModernaTX, Inc. $1,014.00 05/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974269
Principal investigator 1 ModernaTX, Inc. $500.00 05/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006403
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006407
Principal investigator 1 ModernaTX, Inc. $310.50 05/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974241
Principal investigator 1 ModernaTX, Inc. $3,211.00 05/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974275
Principal investigator 1 ModernaTX, Inc. $93.58 05/08/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006411
Principal investigator 1 ModernaTX, Inc. $11,934.00 05/08/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006423
Principal investigator 1 ModernaTX, Inc. $46.79 05/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006397
Principal investigator 1 ModernaTX, Inc. $264.00 05/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006405
Principal investigator 1 ModernaTX, Inc. $1,326.00 05/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006445
Principal investigator 1 ModernaTX, Inc. $34,481.20 04/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006419
Principal investigator 1 ModernaTX, Inc. $33,911.46 04/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006421
Principal investigator 1 ModernaTX, Inc. $21,294.45 04/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006435
Principal investigator 1 ModernaTX, Inc. $500.00 04/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006401
Principal investigator 1 ModernaTX, Inc. $1,547.00 03/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006395
Principal investigator 1 ModernaTX, Inc. $151.36 03/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006467
Principal investigator 1 ModernaTX, Inc. $30,628.00 03/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006417
Principal investigator 1 ModernaTX, Inc. $31,231.86 03/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006437
Principal investigator 1 ModernaTX, Inc. $21,351.66 03/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006469
Principal investigator 1 ModernaTX, Inc. $100.00 03/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998709
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974273
Principal investigator 1 ModernaTX, Inc. $1,966.50 03/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974243
Principal investigator 1 ModernaTX, Inc. $12,339.96 03/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974255
Principal investigator 1 ModernaTX, Inc. $676.00 03/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974261
Principal investigator 1 ModernaTX, Inc. $6,749.04 03/03/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974259
Principal investigator 1 ModernaTX, Inc. $3,825.50 02/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252974251
Principal investigator 1 ModernaTX, Inc. $34,876.40 02/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006393
Principal investigator 1 ModernaTX, Inc. $44,796.62 02/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006449
Principal investigator 1 ModernaTX, Inc. $31,231.86 02/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006463
Principal investigator 1 ModernaTX, Inc. $4,134.80 02/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006465
Principal investigator 1 ModernaTX, Inc. $1,547.00 02/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006415
Principal investigator 1 ModernaTX, Inc. $19,829.74 02/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252974247
Principal investigator 1 ModernaTX, Inc. $2,000.00 02/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252974249
Principal investigator 1 ModernaTX, Inc. $1,575.00 02/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252974263
Principal investigator 1 ModernaTX, Inc. $1,242.50 02/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252974265
Principal investigator 1 ModernaTX, Inc. $3,000.00 02/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults No dispute reported 06/30/2026 1252974267
Principal investigator 1 ModernaTX, Inc. $15,742.35 01/30/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998723
Principal investigator 1 ModernaTX, Inc. $7,892.16 01/29/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252998697
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $10,444.10 01/28/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy No dispute reported 06/30/2026 1214123838
Principal investigator 1 ModernaTX, Inc. $30,980.84 01/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006391
Principal investigator 1 ModernaTX, Inc. $58,920.90 01/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006413
Principal investigator 1 ModernaTX, Inc. $35,212.32 01/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006429
Principal investigator 1 ModernaTX, Inc. $5,553.80 01/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006433
Principal investigator 1 ModernaTX, Inc. $42,588.90 01/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006443
Principal investigator 1 ModernaTX, Inc. $28,019.68 01/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006389
Principal investigator 1 ModernaTX, Inc. $158,283.30 01/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006409
Principal investigator 1 ModernaTX, Inc. $24,282.28 01/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006427
Principal investigator 1 ModernaTX, Inc. $83,729.70 01/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006439
Principal investigator 1 ModernaTX, Inc. $1,698.74 01/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006441
Principal investigator 1 ModernaTX, Inc. $22,714.08 01/23/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006455
Principal investigator 1 ModernaTX, Inc. $46.79 01/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006385
Principal investigator 1 ModernaTX, Inc. $9,724.00 01/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006387
Principal investigator 1 ModernaTX, Inc. $793.80 01/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006399
Principal investigator 1 ModernaTX, Inc. $1,500.00 01/08/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006459